Intuitive Surgical Forecast, price target & analysts
Intuitive Surgical Target price 2025 - Analyst rating & recommendation
Intuitive Surgical Classifications & Recommendation:
Intuitive Surgical Price Target
| Target Price | $580.03 |
| Price | $508.13 |
| Potential | 14.15% |
| Number of Estimates | 26 |
| 26 Analysts have issued a price target Intuitive Surgical 2026 . The average Intuitive Surgical target price is $580.03. This is 14.15% higher than the current stock price. The highest price target is $675.00 32.84% , the lowest is $470.00 7.50% . | |
| A rating was issued by 35 analysts: 20 Analysts recommend Intuitive Surgical to buy, 14 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Intuitive Surgical stock has an average upside potential 2026 of 14.15% . Most analysts recommend the Intuitive Surgical stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
28 Analysts have issued a sales forecast Intuitive Surgical 2025 . The average Intuitive Surgical sales estimate is $9.7b . This is 10.88% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $9.9b 13.80% , the lowest is $9.5b 8.99% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $8.4b | 17.24% |
|---|---|---|
| 2025 | $9.7b | 15.69% |
| 2026 | $11.2b | 15.48% |
| 2027 | $12.9b | 15.55% |
| 2028 | $14.9b | 15.86% |
| 2029 | $16.5b | 10.68% |
21 Analysts have issued an Intuitive Surgical EBITDA forecast 2025. The average Intuitive Surgical EBITDA estimate is $4.0b . This is 40.66% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.8b 71.58% , the lowest is $3.3b 18.21% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $2.8b | 27.37% |
|---|---|---|
| 2025 | $4.0b | 40.94% |
| 2026 | $4.6b | 16.42% |
| 2027 | $5.5b | 19.78% |
| 2028 | $6.4b | 16.20% |
| 2029 | $7.2b | 11.96% |
EBITDA Margin
| 2024 | 33.58% | 8.64% |
|---|---|---|
| 2025 | 40.91% | 21.83% |
| 2026 | 41.24% | 0.81% |
| 2027 | 42.75% | 3.66% |
| 2028 | 42.88% | 0.30% |
| 2029 | 43.37% | 1.14% |
12 Intuitive Surgical Analysts have issued a net profit forecast 2025. The average Intuitive Surgical net profit estimate is $2.5b . This is 0.94% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.7b 9.53% , the lowest is $2.3b 6.30% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $2.3b | 27.63% |
|---|---|---|
| 2025 | $2.5b | 7.23% |
| 2026 | $3.0b | 19.86% |
| 2027 | $3.5b | 19.43% |
| 2028 | $4.2b | 18.88% |
Net Margin
| 2024 | 27.55% | 8.87% |
|---|---|---|
| 2025 | 25.53% | 7.33% |
| 2026 | 26.50% | 3.80% |
| 2027 | 27.39% | 3.36% |
| 2028 | 28.11% | 2.63% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
12 Analysts have issued a Intuitive Surgical forecast for earnings per share. The average Intuitive Surgical EPS is $6.88 . This is 0.88% higher than earnings per share in the financial year 2024. The highest EPS forecast is $7.47 9.53% , the lowest is $6.39 6.30% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $6.42 | 27.63% |
|---|---|---|
| 2025 | $6.88 | 7.17% |
| 2026 | $8.25 | 19.91% |
| 2027 | $9.86 | 19.52% |
| 2028 | $11.72 | 18.86% |
P/E ratio
| Current | 74.49 | 12.66% |
|---|---|---|
| 2025 | 73.81 | 0.91% |
| 2026 | 61.58 | 16.57% |
| 2027 | 51.56 | 16.27% |
| 2028 | 43.37 | 15.88% |
Based on analysts' sales estimates for 2025, the Intuitive Surgical stock is valued at an EV/Sales of 17.91 and an P/S ratio of 18.84 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 19.86 | 16.14% |
|---|---|---|
| 2025 | 17.91 | 9.82% |
| 2026 | 15.51 | 13.41% |
| 2027 | 13.42 | 13.45% |
| 2028 | 11.58 | 13.69% |
| 2029 | 10.47 | 9.65% |
P/S ratio
| Current | 20.89 | 17.74% |
|---|---|---|
| 2025 | 18.84 | 9.81% |
| 2026 | 16.31 | 13.41% |
| 2027 | 14.12 | 13.45% |
| 2028 | 12.19 | 13.69% |
| 2029 | 11.01 | 9.65% |
Intuitive Surgical...
Current Intuitive Surgical Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Evercore ISI Group |
In-Line
➜
In-Line
|
Unchanged | Apr 23 2025 |
| Baird |
Outperform
➜
Outperform
|
Unchanged | Apr 23 2025 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Apr 23 2025 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Apr 23 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 23 2025 |
| Baird |
Outperform
➜
Outperform
|
Unchanged | Mar 18 2025 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Mar 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Evercore ISI Group:
In-Line
➜
In-Line
|
Apr 23 2025 |
|
Unchanged
Baird:
Outperform
➜
Outperform
|
Apr 23 2025 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Apr 23 2025 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Apr 23 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 23 2025 |
|
Unchanged
Baird:
Outperform
➜
Outperform
|
Mar 18 2025 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Mar 17 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
